Loading

Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radiation Therapy

SRT-100, a Low-energy X-ray Technology, Used at Site of Keloidectomy Treatment

BOCA RATON, Fla.Dec. 6, 2018 /PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announced today positive results of a multicenter case series of patients treated with the SRT-100™ following complete surgical keloidectomy. Of the 297 patients treated post-operatively with superficial radiation, there were only nine cases of observed clinical keloid recurrences, or a recurrence rate of 3%. The results of the study were published in the November issue of SKIN, The Journal of Cutaneous Medicine.

Read the full press release here.

Share to:

Contact Us

Fill out the form below to find out more!